MABWELL-B (02493) achieved operating revenue of approximately RMB621 million in the first three quarters, up 9.77% year on year.

MABWELL-B (02493) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB621 million, up 9.77% year on year; net loss attributable to shareholders of the listed company was approximately RMB678 million, with basic loss per share of RMB1.6. The company continues to deepen the commercialization layout of the global market. In the domestic market, pharmaceutical sales revenue in the third quarter of 2026 reached approximately RMB123 million, up 122.13% year on year. In overseas markets, in July 2026, the company reached licensing agreements with partners in the Philippines, Vietnam, and Malaysia to jointly advance the local registration and commercialization of 9MW0813; in the same month, the company reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc., under which the two parties will engage in in-depth cooperation on the registration, production, and commercialization of 9MW0813 in the Gulf Arab states; in August 2026, wholly-owned subsidiary Taikang Biotech successfully passed the GMP on-site inspection by Brazil's National Health Surveillance Agency (ANVISA) for two denosumab injection products, 9MW0311 (Mailishu) and 9MW0321 (Maiweijian), marking the second time Mabwell has obtained a GMP certificate issued by a drug regulatory authority of a PIC/S member country, following Jordan.